Biotech firm InterVenn Biosciences raises P10 billion for cancer research
By securing P10 Billion Series C financing SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management, Intervenn Biosciences will continue to develop and commercialize a blood-based test for…
You must be logged in to post a comment.